Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 9303-9309

  Tas, Faruk ^a   Karabulut, Senem ^a   Bilgin, Elif ^a   Tastekin, Didem ^a   Duranyildiz, Derya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; IGF 1; IGFBP 3; Prognostic factor; Serum

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; BREAST NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS;

EID: 84919838426     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2224-2     Document Type: Article

References (12)

1. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.
2. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11:530–42.
3. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, et al. IGF-1, IGFBP-3 and breast cancer risk in women: the European Prospective Investigation into Cancer And Nutrition (EPIC). Endocrine Rel Cancer. 2006;13:593–605.
4. Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB, et al. IGF1 and risk of additional breast cancer in the WHEL study. Endocrine Rel Cancer. 2011;18:235–44.
5. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harvey VJ, Thompson PI, et al. Serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg. 2003;73:905–8.
6. Hankinson SE, Willett WC, Colditz GA, Hunter DJ. Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet. 1998;351:1393–6.
7. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting ınsulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20: 42–51
8. Pasanisi P, Venturelli E, Morelli D, Fontana L, Secreto G, Berrino F. Serum insulin-like growth factor-1 and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev. 2008;17:1719–22.
9. Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-1 and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology. 1999;57:330–40.
10. Hartog H, Boezen HM, de Jong MM, Schaapveld M, Wesseling J, van der Graaf WTA. Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast. 2013;22:1155–60.
11. Oh Y. IGF-independent regulation of breast cancer growth by IGF binding proteins. Breast Cancer Res Treat. 1998;47:283–93.
12. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem. 1993;52:196–205.